Your semaglutide journey week by week: a practical guide to Wegovy

Step 1, Weeks 1–4: the starter dose and what it's actually doing

Treatment opens at 0.25 mg weekly. That dose is often described as a tolerability step rather than a working dose, and that framing is accurate, the 0.25 mg pen's primary job is to introduce your gut and appetite system to semaglutide gradually. Expect relatively little change on the scales during this first month. That's not a sign the medicine isn't working; it's the design.

What you may notice instead is appetite behaving differently. Some people feel full mid-meal earlier than usual. Others experience nausea, particularly after eating, especially fatty or rich food. Loose stools, constipation, or a slightly queasy morning feeling are all common in week one or two. They generally settle. Keep meals smaller, eat slowly, and stay well hydrated. The NHS semaglutide medicines page gives a clear breakdown of which side effects are common versus those that need medical attention.

One practical anchor many patients find useful: keep your pen in the fridge door at a consistent spot and inject on the same day each week, pairing it with something fixed in your routine helps with adherence without needing reminders.

Step 2, Weeks 5–16: dose increases and appetite genuinely shifting

At week five your prescriber moves you to 0.5 mg. The standard Wegovy titration continues through 1.0 mg and 1.7 mg, with roughly four weeks at each level. Every increase can bring a temporary return of nausea or digestive disruption, this is your gut re-adjusting to the higher concentration of semaglutide.

This is also the phase where most people notice appetite suppression becoming more pronounced and consistent. Portion sizes that previously felt normal start to feel like too much. Cravings for high-calorie foods often quieten. Weight loss typically becomes measurable and regular from around weeks 8–12 once you're past the 0.5 mg or 1.0 mg threshold. It's worth reading more about the Wegovy week-by-week experience if you want a more granular look at what each individual dose change feels like.

Energy can be inconsistent during this phase, partly from eating less, partly from the body adapting. Protein intake matters here. So does drinking enough water. If GI symptoms are severe or persistent, your prescriber can discuss whether slowing the titration makes sense; that's a clinical conversation, not something to manage alone. You can explore what week five on Wegovy is typically like for a closer look at that transition.

Step 3, Weeks 17 onwards: reaching the 2.4 mg maintenance dose

The standard maintenance dose for Wegovy is 2.4 mg weekly. Most people reach it around week seventeen to twenty, depending on their tolerance at each step. This is where the bulk of the weight loss data from the STEP 1 trial applies: over 68 weeks, participants on 2.4 mg semaglutide lost an average of around 15% of their body weight alongside a reduced-calorie diet and increased physical activity, compared with around 2.4% on placebo. That trial, published in the New England Journal of Medicine, enrolled nearly 2,000 adults with obesity and remains the core evidence base for Wegovy's UK licence.

Appetite suppression at 2.4 mg tends to be more stable than during the earlier escalation phase. Weight loss generally continues, though the rate often slows as the body finds a new equilibrium. Plateaus can occur, they're normal and don't always mean treatment is failing. If you'd like a broader sense of how the full Wegovy journey unfolds from first dose to maintenance, that guide covers the arc many patients find useful to read before reaching this stage. For context on how the journey looks at the six-week mark, the week six on Wegovy guide covers a period many people find particularly instructive.

Since March 2026 a 7.2 mg dose has also been available for eligible patients (approved by the MHRA in April 2026) which trials suggest produces around 20.7% average weight loss. Whether that's appropriate for you is a question for your prescriber, not a decision to make from reading about it.

Ongoing: monitoring, reviews, and the longer game

Semaglutide for weight management is not a short course. The STEP 1 trial ran for 68 weeks, and the evidence base is built on sustained use alongside meaningful lifestyle change. Regular clinical review matters throughout, not just at the start. At nume, every repeat order goes back to a GPhC-registered prescriber before it's dispensed, not as a formality, but because dose, tolerance and health status genuinely change over time.

Side effects can emerge at any point, though serious ones are uncommon. The MHRA has highlighted acute pancreatitis as an infrequent but important risk with GLP-1 medicines, severe, persistent abdominal pain that radiates to the back needs prompt medical assessment, not a wait-and-see approach. Any suspected side effect can be reported at the MHRA's Yellow Card scheme.

Questions about cost and how private prescribing works sit on the Wegovy overview page, which covers pricing context alongside the clinical picture. Patients based locally may also find it helpful to read about accessing Wegovy in Walsall, including how local prescribing and collection options work. The full landscape of weight-loss treatment options (including how semaglutide fits alongside other licensed medicines) is on the weight loss treatments overview. When you're ready to understand whether Wegovy suits your situation specifically, speaking to our prescribers is the place to start, consultations are free, reviewed the same day by a real clinician, and come with no obligation.